Drug profile · INN
alglucosidase alfa
MYOZYME
alglucosidase alfa (MYOZYME) is a starch hydrolytic enzyme. Route of administration: iv (infusion). Current US regulatory status: approved.
Drug details — alglucosidase alfa
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- IV (INFUSION)
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
alglucosidase alfa (MYOZYME) is a starch hydrolytic enzyme. Route of administration: iv (infusion). Current US regulatory status: approved.
Key facts
Mechanism of action
Starch hydrolytic enzyme
Primary target: Starch
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is alglucosidase alfa?
alglucosidase alfa (MYOZYME) is a starch hydrolytic enzyme. Route of administration: iv (infusion). Current US regulatory status: approved.
What is the brand name for alglucosidase alfa?
MYOZYME is a marketed brand name for alglucosidase alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of alglucosidase alfa?
alglucosidase alfa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.